Europlasma, listed on Euronext Paris under the ticker ALEUP, has been going through a particularly turbulent period since spring 2026. Between the judicial recovery of its subsidiary FDB Industries, a dilutive bond financing, and a project to divest its defense activities, the stock embodies both the hopes tied to cleantech and the warning signals typical of struggling micro-capitalizations. Sorting through these elements requires looking at recent facts without filters.
FDB Industries in judicial recovery: the subsidiary risk that needs to be assessed
On June 30, 2026, Europlasma requested the opening of a judicial recovery procedure for FDB Industries from the commercial court of Lorient, after consulting the CSE in an extraordinary meeting. The court placed the subsidiary in recovery with a three-month observation period. On the day of the announcement, Europlasma’s stock fell by 25% during the session in Paris.
FDB Industries is not a marginal subsidiary. It carries a part of the group’s industrial activity, and its judicial protection raises questions about the continuity of operations. The court subsequently authorized the continuation of activities until October 15, 2026, which postpones the deadline without eliminating it.
For an investor, this situation creates direct legal uncertainty. If FDB does not find a buyer or a viable plan before the end of the observation period, the consequences for Europlasma’s consolidated balance sheet could be severe. The available data does not allow for a conclusion about the outcome of this procedure at this stage.
Dilutive financing through convertible bonds: the mechanism weighing on the ALEUP share price
Alongside the difficulties at FDB, Europlasma has implemented a financing program through convertible bonds into new shares. In April 2026, the group drew the first two tranches for a nominal amount of 2 million euros, covering 400 convertible bonds.
Those interested in the case will find an analysis of Europlasma’s stock on Impact Patrimoine that details the implications of this type of financial arrangement for existing shareholders.
This financing method has a well-documented mechanical effect on small caps: each conversion of a bond into new shares increases the number of shares outstanding and dilutes the participation of existing shareholders. On a stock that is already very volatile and has a low market capitalization, this additional selling pressure amplifies downward movements.
The repeated use of this type of instrument reflects a difficulty in raising funds through more traditional means (capital increase with maintenance of preferential rights, bank debt). It is a signal that cash management remains under pressure.
Divestment of defense activities: a still uncertain strategic pivot
In June 2026, Europlasma announced a plan to divest its activities in the defense sector for an announced amount of 150 million euros. This figure has attracted attention, but several elements warrant caution.
- The project remains at the discussion stage, and no finalization has been officially confirmed as of the writing of this article.
- Deputy Aurélie Trouvé publicly described this amount as surprising, highlighting a potential gap with the actual valuation of the concerned assets.
- The group has confirmed it is continuing discussions, without providing a specific timeline or details about the potential buyer.
If this divestment goes through, it would radically change Europlasma’s scope by refocusing it on its environmental activities (decontamination, plasma gasification). Conversely, if negotiations fail, the group would retain a heterogeneous portfolio of activities with ongoing pressing financing needs.
Europlasma on the stock market: risk profile for the individual investor
The Europlasma case combines several characteristics that make it a high-risk stock, well beyond the usual volatility of small French capitalizations.
- An active judicial recovery on an industrial subsidiary, with an uncertain outcome.
- Financing through convertible bonds that mechanically dilutes existing shareholders with each tranche drawn.
- A divestment project at 150 million euros whose realization remains hypothetical.
- Recent press articles (Le Monde, La Dépêche, Le Figaro) describing a multiplication of troubles for this “serial acquirer of struggling companies”.
The thematic positioning on decarbonization and decontamination remains an argument put forward by the company. The plasma torch gasification technology (CHO-Power) meets real needs in the treatment of industrial waste. But an attractive sector positioning does not compensate for a fragile financial structure.
What investors are watching until the end of 2026
Three deadlines are capturing the market’s attention. First, the outcome of the observation period for FDB Industries, expected around October 2026. Next, the concrete advancement of the defense divestment project and the potential publication of a firm agreement. Finally, the pace of drawing the bond tranches and its impact on the float.
The analyst consensus, as seen on Boursorama, remains very limited on this stock, reflecting the difficulty in modeling the future results of a group undergoing restructuring. The lack of medium-term financial visibility is the main obstacle for institutional investors.
Europlasma remains a case where the investment thesis relies less on solid financial fundamentals than on a turnaround bet. The coming months, with the court’s decision on FDB and the clarification of the divestment project, will provide determining elements. As long as these uncertainties persist, the balance between the risk taken and the potential gain clearly leans towards risk.